NCT02919670View on ClinicalTrials.gov

A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma

NACompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

May 31, 2019

Study Completion Date

July 31, 2020

Conditions
Multiple MyelomaNon-Hodgkin's Lymphoma
Interventions
DIETARY_SUPPLEMENT

Enterade

DIETARY_SUPPLEMENT

Placebo

OTHER

Standard Supportive Care

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Entrinsic Health
All Listed Sponsors
collaborator

Entrinsic Health

UNKNOWN

lead

Dana-Farber Cancer Institute

OTHER

NCT02919670 - A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter